Author

F. Barlesi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Approach:statistical model· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Boyer· 2 shared S. Benzekry· 2 shared A. Zarubica· 1 shared B. Malissen· 1 shared B. Schneider· 1 shared C. Degos· 1 shared C. Demerle· 1 shared C. Pouypoudat· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Boyer

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

C. Demerle, L. Gorvel, M. Mello, S. Pastor, C. Degos, A. Zarubica, F. Angelis, F. FIORE, J. Nunes, B. Malissen, L. Greillier, G. Guittard, H. Luche, F. Barlesi, D. Olive

bioRxiv · Nov 4, 2022 · PreprintImmunology

Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer

M. Bilous, C. Serdjebi, A. Boyer, P. Tomasini, C. Pouypoudat, D. Barbolosi, F. Barlesi, F. Chomy, S. Benzekry

The paper develops a mathematical model to predict brain metastasis dynamics in NSCLC using clinical data and estimates tumor age and latency phases.

bioRxiv · Aug 27, 2019Cancer Biology

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer

B. Schneider, A. Boyer, J. Ciccolini, F. Barlesi, K. Wang, S. Benzekry, J. P. Mochel

The paper predicts optimal dosing gaps for BEV-PEM/CIS in mice and humans to maximize efficacy while minimizing toxicity.

bioRxiv · Feb 5, 2019Pharmacology & Toxicology